GlycoNAVI: CheGly (Chemical Glycosylation)
ACT

Gilvocarcin V

ID Compound Name Target Name Species Assay Method Activity Value Conditions DOI
act1478Gilvocarcin VStaphylococcusb aureus  ATCC 6538PMIC (μg/ml)0.0510.7164/antibiotics.34.266
act1480Gilvocarcin VBacillus subtilis  No. 10707MIC (μg/ml)0.7810.7164/antibiotics.34.266
act1482Gilvocarcin VKlebsiella pneumoniaeMIC (μg/ml)10010.7164/antibiotics.34.266
act1484Gilvocarcin VEscherichia coli  ATCC 26MIC (μg/ml)2510.7164/antibiotics.34.266
act1486Gilvocarcin VShigella sonnei  ATCC 9290MIC (μg/ml)10010.7164/antibiotics.34.266
act1488Gilvocarcin VSarcinoma 180T/CN.T.Dose (mg/kg)    5010.7164/antibiotics.34.266
act1489Gilvocarcin VSarcinoma 180T/C0.81Dose (mg/kg)    10010.7164/antibiotics.34.266
act1490Gilvocarcin VSarcinoma 180T/C0.76Dose (mg/kg)     20010.7164/antibiotics.34.266
act1491Gilvocarcin VSarcinoma 180T/C0.46Dose (mg/kg)     40010.7164/antibiotics.34.266
act1492Gilvocarcin Vlymphocytic leukemia P388ISL %32Dose (mg/kg) 5010.7164/antibiotics.34.266
act1493Gilvocarcin Vlymphocytic leukemia P388ISL %35Dose (mg/kg) 10010.7164/antibiotics.34.266
act1494Gilvocarcin Vlymphocytic leukemia P388ISL %47Dose (mg/kg) 20010.7164/antibiotics.34.266
act1495Gilvocarcin Vlymphocytic leukemia P388ISL %57Dose (mg/kg) 40010.7164/antibiotics.34.266
act1496Gilvocarcin VSarcinoma 180T/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)0.90 3.8 11500Dose (mg/kg/day) 50 Schedule                  day 110.7164/antibiotics.34.266
act1497Gilvocarcin VSarcinoma 180T/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)0.85 4.1   Dose (mg/kg/day) 100 Schedule                  day 110.7164/antibiotics.34.266
act1498Gilvocarcin VSarcinoma 180T/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)0.72 3.4  Dose (mg/kg/day) 200 Schedule                  day 110.7164/antibiotics.34.266
act1499Gilvocarcin VSarcinoma 180T/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)400 Day 1 0.48 1.2  Dose (mg/kg/day) 400 Schedule                  day 110.7164/antibiotics.34.266
act1500Gilvocarcin VSarcinoma 180T/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)0.85 3.5 10900Dose (mg/kg/day) 25 Schedule                  Day 1~5 10.7164/antibiotics.34.266
act1501Gilvocarcin VSarcinoma 180T/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)0.72 2.8 13400Dose (mg/kg/day) 50 Schedule                  Day 1~5 10.7164/antibiotics.34.266
act1502Gilvocarcin VSarcinoma 180T/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)0.37 0.5 12100Dose (mg/kg/day) 100 Schedule                  Day 1~5 10.7164/antibiotics.34.266
act1503Gilvocarcin VSarcinoma 180\nT/C (day 7)\nBody wt. change (g)\nWBC (/mm^3)0.34 -0.8 10800Dose (mg/kg/day) 200 Schedule                  Day 1~5 10.7164/antibiotics.34.266
act1504Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)18.8±4.4 24 0/5Exp. 1. Dose (mg/kg)        12.5 Schedule               Day 110.7164/antibiotics.34.266
act1505Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)18.4±3.1 21 0/5Exp. 1. Dose (mg/kg)        25 Schedule               Day 110.7164/antibiotics.34.266
act1506Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)17.4±3.6 14 0/5Exp. 1. Dose (mg/kg)        50 Schedule               Day 110.7164/antibiotics.34.266
act1507Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)Day 1 23.3±3.6 53 1/5Exp. 1. Dose (mg/kg)        100 Schedule               Day 110.7164/antibiotics.34.266
act1508Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)27.0±9.4 78 2/5Exp. 1. Dose (mg/kg)        200 Schedule               Day 110.7164/antibiotics.34.266
act1509Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)29.7±9.1 95 2/5Exp. 1. Dose (mg/kg)        400 Schedule               Day 110.7164/antibiotics.34.266
act1510Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)20.4±3.6 7 0/5Exp. 2. Dose (mg/kg)        5 Schedule               Day 1~510.7164/antibiotics.34.266
act1511Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)22.3±3.3 17 0/5Exp. 2. Dose (mg/kg)        10 Schedule               Day 1~510.7164/antibiotics.34.266
act1512Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)30.0±0 50 2/5Exp. 2. Dose (mg/kg)        20 Schedule               Day 1~510.7164/antibiotics.34.266
act1513Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)43.0±2.0 126 3/5Exp. 2. Dose (mg/kg)        40 Schedule               Day 1~510.7164/antibiotics.34.266
act1514Gilvocarcin VEhrlich carcinomaSuvival days\nILS (%)\nSurvivours (60 days)57 200 4/5Exp. 2. Dose (mg/kg)        80 Schedule               Day 1~510.7164/antibiotics.34.266
act1515Gilvocarcin VEhrlich ascites carcinomaSuvival days\nILS (%)\nSurvivours (60 days)16.3±2.4 12 0/6Dose (mg/kg)        12.510.7164/antibiotics.34.266
act1516Gilvocarcin VEhrlich ascites carcinomaSuvival days\nILS (%)\nSurvivours (60 days)16.5±2.7 14 0/6Dose (mg/kg)        2510.7164/antibiotics.34.266
act1517Gilvocarcin VEhrlich ascites carcinomaSuvival days\nILS (%)\nSurvivours (60 days)18.0±2.4 24 0/6Dose (mg/kg)        5010.7164/antibiotics.34.266
act1518Gilvocarcin VEhrlich ascites carcinomaSuvival days\nILS (%)\nSurvivours (60 days)20.7±4.5 43 0/6Dose (mg/kg)        10010.7164/antibiotics.34.266
act1519Gilvocarcin VEhrlich ascites carcinomaSuvival days\nILS (%)\nSurvivours (60 days)20.0±3.2 38 0/6Dose (mg/kg)        20010.7164/antibiotics.34.266
act1520Gilvocarcin VEhrlich ascites carcinomaSuvival days\nILS (%)\nSurvivours (60 days)27.3±8.7 89 0/6Dose (mg/kg)        40010.7164/antibiotics.34.266
act1521Gilvocarcin VMeth 1 fibrosarcomaILS (%)\nSurvivours (60 days)42 0/5Dose (mg/kg)        25 Schedule Day 110.7164/antibiotics.34.266
act1522Gilvocarcin VMeth 1 fibrosarcomaILS (%)\nSurvivours (60 days)95 0/5Dose (mg/kg)        50 Schedule Day 110.7164/antibiotics.34.266
act1523Gilvocarcin VMeth 1 fibrosarcomaILS (%)\nSurvivours (60 days)136 0/5Dose (mg/kg)        100 Schedule Day 110.7164/antibiotics.34.266
act1524Gilvocarcin VMeth 1 fibrosarcomaILS (%)\nSurvivours (60 days)180 1/5Dose (mg/kg)        200 Schedule Day 110.7164/antibiotics.34.266
act1525Gilvocarcin VMeth 1 fibrosarcomaILS (%)\nSurvivours (60 days)153 4/5Dose (mg/kg)        400 Schedule Day 110.7164/antibiotics.34.266
act1526Gilvocarcin VMH 134Suvival days\nILS (%)\nSurvivours (60 days)17.5±3.5 6 0/6Dose (mg/kg) 2510.7164/antibiotics.34.266
act1527Gilvocarcin VMH 134Suvival days\nILS (%)\nSurvivours (60 days)21.3±3.6 29 0/6Dose (mg/kg) 5010.7164/antibiotics.34.266
act1528Gilvocarcin VMH 134Suvival days\nILS (%)\nSurvivours (60 days)31.5±4.5 91 2/6Dose (mg/kg) 10010.7164/antibiotics.34.266
act1529Gilvocarcin VMH 134Suvival days\nILS (%)\nSurvivours (60 days)53.0±7.8 221 3/6Dose (mg/kg) 20010.7164/antibiotics.34.266
act1530Gilvocarcin VMH 134Suvival days\nILS (%)\nSurvivours (60 days)39.5±9.1 139 2/6Dose (mg/kg) 40010.7164/antibiotics.34.266
act1531Gilvocarcin VP388 leukemiaSuvival days\nILS (%)12.6±1.0 34.0Exp. 1. Dose (mg/kg) 50 Schedule Day 110.7164/antibiotics.34.266
act1532Gilvocarcin VP388 leukemiaSuvival days\nILS (%)12.8±0.7 36.1Exp. 1. Dose (mg/kg)        100 Schedule Day 110.7164/antibiotics.34.266
act1533Gilvocarcin VP388 leukemiaSuvival days\nILS (%)14.0±1.5 48.9Exp. 1. Dose (mg/kg)        200 Schedule Day 110.7164/antibiotics.34.266
act1534Gilvocarcin VP388 leukemiaSuvival days\nILS (%)14.8±0.7 57.4Exp. 1. Dose (mg/kg)        400 Schedule Day 110.7164/antibiotics.34.266
act1535Gilvocarcin VP388 leukemiaSuvival days\nILS (%)12.8±1.5 39.1Exp. 2. Dose (mg/kg)        12.5 Schedule Day 1~510.7164/antibiotics.34.266
act1536Gilvocarcin VP388 leukemiaSuvival days\nILS (%)15.6±1.4 69.6Exp. 2. Dose (mg/kg) 25 Schedule Day 1~510.7164/antibiotics.34.266
act1537Gilvocarcin VP388 leukemiaSuvival days\nILS (%)14.8±1.9 60.8Exp. 2. Dose (mg/kg) 50 Schedule Day 1~510.7164/antibiotics.34.266
act1538Gilvocarcin VP388 leukemiaSuvival days\nILS (%)15.0±2.3 63.0Exp. 2. Dose (mg/kg) 100 Schedule Day 1~510.7164/antibiotics.34.266
act1539Gilvocarcin VP388 leukemiaSuvival days\nILS (%)15.6±0.8 69.6Exp. 2. Dose (mg/kg) 200 Schedule Day 1~510.7164/antibiotics.34.266
act1540Gilvocarcin VP388 leukemiaSuvival days\nILS (%)10.8±0.7 11.3Exp. 3. Dose (mg/kg)        50 Schedule Day 110.7164/antibiotics.34.266
act1541Gilvocarcin VP388 leukemiaSuvival days\nILS (%)12.4±0.8 27.8Exp. 3. Dose (mg/kg)        100 Schedule Day 110.7164/antibiotics.34.266
act1542Gilvocarcin VP388 leukemiaSuvival days\nILS (%)12.8±1.2 32.0Exp. 3. Dose (mg/kg)        200 Schedule Day 110.7164/antibiotics.34.266
act1548Gilvocarcin VB 16 melanomaSuvival days (Mean±S.D.)\nILS (%)21.5±1.8 5Dose (mg/kg)        2510.7164/antibiotics.34.266
act1549Gilvocarcin VB 16 melanomaSuvival days (Mean±S.D.)\nILS (%)25.0±5.0 22Dose (mg/kg)        5010.7164/antibiotics.34.266
act1550Gilvocarcin VB 16 melanomaSuvival days (Mean±S.D.)\nILS (%)23.3±2.2 14Dose (mg/kg)        10010.7164/antibiotics.34.266
act1551Gilvocarcin VB 16 melanomaSuvival days (Mean±S.D.)\nILS (%)27.2±6.7 33Dose (mg/kg)        20010.7164/antibiotics.34.266
act1552Gilvocarcin VB 16 melanomaSuvival days (Mean±S.D.)\nILS (%)28.6±6.3 40Dose (mg/kg)        40010.7164/antibiotics.34.266
act1553Gilvocarcin VB 16 melanomaSuvival days (Mean±S.D.)\nILS (%)27.5±5.3 34Dose (mg/kg)        80010.7164/antibiotics.34.266
act1554Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C864±430 0.91Dose (mg/kg/day) 50 Day 1210.7164/antibiotics.34.266
act1555Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C673±440 0.73Dose (mg/kg/day) 100 Day 1210.7164/antibiotics.34.266
act1556Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C702±170 0.77Dose (mg/kg/day) 200 Day 1210.7164/antibiotics.34.266
act1557Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C318±164 0.35Dose (mg/kg/day) 400 Day 1210.7164/antibiotics.34.266
act1558Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C1640±591 0.98Dose (mg/kg/day) 50 Day 1510.7164/antibiotics.34.266
act1559Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C1357±506 0.81Dose (mg/kg/day) 100 Day 1510.7164/antibiotics.34.266
act1560Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C1266±191 0.75Dose (mg/kg/day) 200 Day 1510.7164/antibiotics.34.266
act1561Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C594±283 0.35Dose (mg/kg/day) 400 Day 1510.7164/antibiotics.34.266
act1562Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C5034±1371 1.05Dose (mg/kg/day) 50 Day 1810.7164/antibiotics.34.266
act1563Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C4197±716 0.88Dose (mg/kg/day) 100 Day 1810.7164/antibiotics.34.266
act1564Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C3801±728 0.80Dose (mg/kg/day) 200 Day 1810.7164/antibiotics.34.266
act1565Gilvocarcin VLewis lung carcinomaTumor volume (Mean±S.D.)\nT/C2065±682 0.43Dose (mg/kg/day) 400 Day 1810.7164/antibiotics.34.266
act1566Gilvocarcin VStreptococcus pneumoniae  9585Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure0.1310.7164/antibiotics.34.266
act1568Gilvocarcin VStreptococcus pyogenes  9604Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure0.1310.7164/antibiotics.34.266
act1570Gilvocarcin VStaphylococcus aureus  9535Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure0.0610.7164/antibiotics.34.266
act1572Gilvocarcin VStaphylococcus aureus (Pen-Res) 9606Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure0.2510.7164/antibiotics.34.266
act1574Gilvocarcin VStreptococcus faecalis 20688Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure0.01610.7164/antibiotics.34.266
act1576Gilvocarcin VEscherichia coli 15119Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>6310.7164/antibiotics.34.266
act1578Gilvocarcin VEscherichia coli 203410-1Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>6310.7164/antibiotics.34.266
act1580Gilvocarcin VKlebsiella pneumoniae 15130Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>6310.7164/antibiotics.34.266
act1582Gilvocarcin VProteus vulgaris 21559Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure210.7164/antibiotics.34.266
act1584Gilvocarcin VSerratia marcescens 20019Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>6310.7164/antibiotics.34.266
act1586Gilvocarcin VEnterococcus cloacae 9659Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>6310.7164/antibiotics.34.266
act1588Gilvocarcin VPsudomonas aeruginosa 9843AMinimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>6310.7164/antibiotics.34.266
act1590Gilvocarcin VTrichophyton rubrum A22789Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure3210.7164/antibiotics.34.266
act1592Gilvocarcin VTrichophyton mentagrophytes  A9870Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure3210.7164/antibiotics.34.266
act1594Gilvocarcin VMicrosporum canis  A9872Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure3210.7164/antibiotics.34.266
act1596Gilvocarcin VMicrosporum canis A22494Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>3210.7164/antibiotics.34.266
act1598Gilvocarcin VCandida albicans  9540Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>3210.7164/antibiotics.34.266
act1600Gilvocarcin VCandida albicans  15049Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>3210.7164/antibiotics.34.266
act1602Gilvocarcin VCandida albicans 15050Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>3210.7164/antibiotics.34.266
act1604Gilvocarcin VCandida tropicalis  15051Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>3210.7164/antibiotics.34.266
act1606Gilvocarcin VCandida krusei  15052Minimum inhibitory concentration (μg/ml), standard 2-fold dilution procedure>3210.7164/antibiotics.34.266